ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection. NEWTON, MA, October 15, 2025 – ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed [...]

ClearB Therapeutics Announces Upcoming Poster Presentation of Pre-Clinical Chronic Hepatitis B Data at EASL 2025. CONCORD, MA, 25 April 2025 — ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an abstract will be presented [...]

ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of pre-clinical chronic hepatitis B data at AASLD 2024. CONCORD, MA, 17 OCTOBER 2024 — ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to [...]

ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2024 CONCORD, MA, 29 May 2024 — ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive a functional cure for Hepatitis B, announced today that two abstracts will be [...]

ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2023 June 20, 2023 09:17 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that [...]

ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022 October 24, 2022 12:50 PM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, [...]

Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract titled “Impact [...]